Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA calls for strongest warning on Essure birth control device

Bayer AG’s Essure birth control implant should carry the strongest safety warning label, U.S. regulators said on Monday, following thousands of complaints about the device. The U.S. Food and Drug Administration also asked the German drugmaker to conduct a post-market study of the device. Essure, acquired by Bayer in 2013, has been the target of […]

Read More »

Patients get mixed reactions from docs over mail-ordered genetic tests

(Reuters Health) – Patients who order direct-to-consumer genetic tests report mixed experiences when they take the results to their doctors, a new study found. About a quarter of people who ordered direct-to-consumer genetic testing from companies like 23andMe reported discussing the results with their primary care doctors. But nearly one in five were not at […]

Read More »

Scientists find Zika increases risk of rare neurological illness

French scientists say they have proved a link between the Zika virus and a nerve syndrome called Guillain-Barre, suggesting countries hit by the Zika epidemic will see a rise in cases of the serious neurological condition.   Guillain-Barre (GBS) is a rare syndrome in which the body’s immune system attacks part of the nervous system. […]

Read More »

Appeals court pauses NYC restaurant salt warning rule

A New York appeals court on Monday temporarily stopped New York City from enforcing a new rule requiring chain restaurants to post warnings on menu items high in sodium.   A judge in the Appellate Division, First Department, granted an interim stay of enforcement of the rule. Starting tomorrow, violators would have been subject to […]

Read More »

Closely watched AstraZeneca cancer drug fails in mesothelioma

A closely watched AstraZeneca drug did not extend lives of patients with the rare cancer mesothelioma when given on its own, but the drugmaker said it still believed the medicine had a role to play in combination treatments. Mesothelioma is a deadly form of cancer that affects the lining of the lungs or abdomen. Patients […]

Read More »

Swiss Basilea says profits still 2-3 years away

Swiss drugmaker Basilea expects to move into profit by 2018, counting on new anti-infection drugs to help mitigate setbacks such as last month’s collapse of efforts to win U.S. approval for an eczema treatment. On Monday, Basilea reported a full-year 2015 net loss of 61.6 million Swiss francs ($60.9 million), bringing total losses since 2011 […]

Read More »

Aldeyra’s eye drug found effective in mid-stage study

Aldeyra Therapeutics Inc said its experimental eye drug proved to be more effective than a placebo in treating itching associated with allergic conjunctivitis in a mid-stage study. Allergic conjunctivitis is a common disease characterized by an inflammation of the membrane that covers the eye, which results in excessive tear production, ocular itching, swelling, and redness. […]

Read More »

New findings could boost type 1 diabetes treatment

For six weeks seven-year-old Bethan Westcott-Storer was feeling listless and losing weight, worrying parents Lizzie and Dean. Now aged nine, she’s the picture of health, having been diagnosed with type 1 diabetes in November 2014, since when she’s been treating herself via an omnipod pump that delivers insulin via a cannula under her skin. “I […]

Read More »

GlaxoSmithKline Officially Begins Search for CEO Replacement

LONDON – Sir Andrew Witty, chief executive officer of British drugmaker GlaxoSmithKline (GSK), will soon be replaced. Company chairman Philip Hampton held a number of recent meetings with shareholders and made it clear that planning for a new CEO will be a board priority, the Yorkshire Post reported this morning.   The Telegraph of London […]

Read More »

Amid Fierce Competition from GlaxoSmithKline, AstraZeneca and Teva, Two of Genentech’s Asthma Drug Trials Disappoint

February 29, 2016 By Mark Terry, Breaking News Staff   Genentech (RHHBY), a division of Switzerland-based Roche Holding AG (RHHBY), announced the results of two Phase III studies of lebrikizumab in patients with severe asthma. One study met its primary endpoint, but not as well as seen in Phase II clinical trials. And in […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom